Epithalamin: Evidence, Mechanism, Dosing & Legal Status

Epithalamin is a bovine pineal-gland polypeptide extract developed by Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology beginning in the 1970s. It is the natural precursor of the synthetic tetrapeptide epitalon (Ala-Glu-Asp-Gly / AEDG), which was rationally distilled from the extract's amino-acid composition and only confirmed to genuinely occur in pineal tissue in 2017.34 It carries one of the more provocative long-term human datasets in the longevity-peptide field — and one of the thinnest in rigor. This monograph separates the two.

This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. Epithalamin is not an FDA-approved drug; it is sold as a "research chemical not for human use" and is prohibited in sport. Dosing figures are reported strictly as published in the literature for completeness — not as recommendations. Telomerase-modulating compounds carry unresolved theoretical cancer-biology concerns. Consult a licensed clinician before any health decision.

What is epithalamin and how does it work?

Epithalamin is not a single defined molecule but a low-molecular-weight polypeptide complex extracted from bovine (and ovine) pineal glands — a "bioregulator" in the Khavinson framework, which holds that organs contain short peptides regulating tissue-specific, age-dependent gene expression.3 Its putative active principle was condensed into the synthetic tetrapeptide epitalon (AEDG, MW about 390.35 Da), described as "developed on the basis of the amino-acid composition of Epithalamin." Per the same review, epitalon is a better antioxidant than epithalamin and active at roughly a thousand-fold lower dose on a mass basis — meaning the extract is the weaker, less-defined parent of the analog.3

Most mechanism is demonstrated for epitalon and extrapolated to the extract. The best human-relevant action is pineal restoration: epithalamin increases pineal synthesis of serotonin, N-acetylserotonin and melatonin and restores the nocturnal melatonin rhythm in aging adults and animals, with a clinical course of the analog raising melatonin-metabolite excretion about 1.6-fold versus placebo (Grade B in humans).23 Preclinically (Grade C), the analog induces hTERT expression, telomerase activity and telomere elongation averaging about 33 percent, extending replicative lifespan of human fibroblasts past the Hayflick limit; it also reduces lipid peroxidation and ROS, raises catalase, glutathione peroxidase and SOD-1, shifts circadian-clock genes, and elevates IL-2 mRNA with effects on T-cell indices.3 Pharmacokinetics are essentially uncharacterized: the 2025 review reports no formal half-life, bioavailability or clearance data for the tetrapeptide, and even less is defined for the heterogeneous extract — consistent with parenteral-only human use.3

What is the evidence by indication?

One caveat governs everything below: virtually all human and most animal evidence for epithalamin originates from a single research group (Khavinson, Morozov, Anisimov, Korkushko and the St. Petersburg and Kiev gerontology institutes). The trials are long but single-center, largely unblinded, placebo-light, report no p-values in abstracts, and have not been independently replicated; even tertiary sources flag the body of work for over-reliance on primary single-source literature.4 The grades reflect that ceiling.

The flagship human study (Khavinson and Morozov, 2003, n=266 over-60s) reported that epithalamin alone reduced mortality 1.6 to 1.8-fold, thymalin alone 2.0 to 2.1-fold, the combination 2.5-fold, and the combination given annually 4.1-fold versus controls, with roughly 2.0 to 2.4-fold fewer acute respiratory illnesses.1 The abstract reports no p-values, no blinding details and no placebo-arm description, and the developers ran the trial — so the effect sizes, while striking, sit well below RCT-grade confidence. The cardiovascular study (Korkushko, 2011) randomized 39 epithalamin-plus-standard-care patients against 40 controls across 6 courses over 3 years and reported roughly 2-fold lower cardiovascular mortality, about 28 percent lower total mortality, normalized melatonin rhythm and improved carbohydrate and lipid metabolism, with extended follow-up to 15 years.2 Small sample and single-center design cap confidence. You can inspect the indexed flagship trial record directly at PubMed (PMID 14523363). The lifespan-extension and anti-tumor effects — increased mean and maximum lifespan in rats, mice and Drosophila, and reduced spontaneous and HER-2/neu mammary tumors in mice — are preclinical only and do not support human claims.4

What doses appear in the literature?

Reported strictly as information, not a protocol — and as published, not a recommendation. Every cited human trial used intramuscular injection of a lyophilized pineal-peptide extract reconstituted in sterile saline.2 The reported regimen was 10 mg IM given as a course of 5 injections at 3-day intervals, with courses repeated 1 to 2 times per year over 3 or more years; notably, the highest mortality benefit in the cohort study tracked with annual repetition rather than a single course.12 No standardized US compounding monograph exists for the extract. Dosing for the synthetic analog (epitalon) differs and is far lower on a mass basis, since the extract is roughly a thousand-fold less potent as an antioxidant per the 2025 review.3

How safe is epithalamin?

The cited human trials report no notable adverse events, and related analog trials likewise reported none — but these were not designed as rigorous safety studies and did not use standardized adverse-event capture, so the absence of reported harm is weak reassurance.13 The major data gap is explicit in the 2025 review: critical safety information is missing, with no formal genotoxicity, carcinogenicity or drug- and food-interaction studies, and the authors call additional toxicity studies essential before approval.3 Because epithalamin is an animal-derived extract rather than a single defined molecule, batch-to-batch composition and bovine-source contamination are additional unquantified concerns. The leading theoretical risk is mechanistic: telomerase reactivation is a recognized feature of many cancers, so chronic telomerase modulation is untested in humans and a legitimate concern with active or prior malignancy — even though the analog showed anti-tumor effects in rodents.3 Immunogenicity, injection-site reactions and sterility/endotoxin risk apply to any injected animal-derived peptide and are explicitly among the FDA's stated concerns for this class.5 Pregnancy, breastfeeding and pediatric use have no data and should be avoided.

What is the FDA and WADA status in 2026?

Epithalamin and epitalon are not FDA-approved and have no NDA, BLA or DailyMed prescribing information for any indication.5 In 2023 the FDA placed epitalon on the 503A Category 2 list, restricting compounding over immunogenicity, manufacturing-impurity and insufficient-human-data concerns.5 In April 2026 the FDA removed epitalon and roughly a dozen other peptides from Category 2, making them merely eligible for consideration for Category 1 / the 503A Bulks List, with a Pharmacy Compounding Advisory Committee meeting scheduled for July 23 to 24, 2026 — but removal from Category 2 does not confer Category 1 or approved status, and each substance still requires individual PCAC review and separate rulemaking.5 Material sold in the US as epithalon or epithalamin is typically marketed "for research use only, not for human consumption." State action is tightening unevenly: Louisiana moved to restrict research peptides including epithalon at the state level in 2024.5 Historically the extract was registered and used as a pharmaceutical in Russia and parts of Eastern Europe, but it is not approved as a drug or supplement in the EU, UK, Canada or Australia.4

For athletes the picture is unambiguous. Epithalamin is not listed by name on the WADA Prohibited List, but as a non-approved pharmacological substance it is captured by category S0 (non-approved substances) — prohibited in sport at all times, with no Therapeutic Use Exemption pathway.5 Any WADA-tested athlete or service member should treat it as banned.

Bottom line. Epithalamin pairs one of the more provocative long-term human datasets in the longevity-peptide field with one of the thinnest in rigor. The geroprotective and melatonin-restoration angle is mechanistically coherent and worth taking seriously, but the human signal is long in duration and weak in design — single-center, largely unblinded, placebo-light, p-value-sparse, run by the compound's developers, and never independently replicated — so it grades B with heavy asterisks, while modern mechanistic and safety work has shifted to the synthetic analog and still lacks formal PK, toxicology and carcinogenicity data. It is not FDA-approved, is prohibited in sport, and should be regarded as investigational. Regulatory facts here are current as of June 2026; the July 23-24, 2026 PCAC outcome was pending at the time of writing and should be re-verified after that date.